Ortho Regenerative Technologies Inc. Presents Advances in Tissue Repair in Multiple Podium Presentations and Posters at the 2016 World Biomaterials Congress

MONTREAL, May 24, 2016 /CNW Telbec/ - Ortho Regenerative Technologies Inc., a regenerative medical device company specializing in the repair of sports medicine injuries (the "Company"), announced today the presentation of key technical advances in the mechanisms underlying the repair of soft tissue injuries through its proprietary biopolymer in 4 podium presentations and 2 poster presentations at the World Biomaterials Congress recently held in Montreal, Canada from May 17-22, 2016.

Based on work led by the Company's scientific founders Michael Buschmann, PhD, Professor and Canada Research Chair, and Caroline Hoemann, PhD, Professor of Chemical Engineering and Biomedical Engineering (both at École Polytechnique de Montréal), the presentations highlighted aspects of the preclinical performance of the products and the unique properties of the Company's proprietary formulations.

The World Biomaterials Congress was attended by over 4,000 scientists from more than 60 countries, representing the single most important meeting in this growing area.

"We are excited to have had 4 podium presentations and the scientific posters focusing on the use of our proprietary biopolymer in the repair of the rotator cuff and meniscus," said Ed Margerrison, Ph.D., President and CEO of Ortho Regenerative Technologies. "As we prepare for the first clinical evaluation of our device candidate in 2017, we are pleased to report this preclinical work demonstrating the potential to reduce the failure rate of surgical treatment of soft tissue injuries, and to provide a clinically meaningful improvement to patients' lives."

Details of the work are as follows:

Podium Presentations

• Presentation Title: "Chitosan-platelet-rich plasma implants for tissue repair - in vitro and in vivo characteristics"
  Session: Biomaterials for Control of Tissue Induction
• Presentation Title: "Chitosan-platelet-rich plasma implants can be injected into meniscus tears to improve repair"
  Session: Biomaterials for Control of Tissue Induction
• Presentation Title: "Guided Bone Marrow Stimulation through a novel biomaterial microparticle approach"
  Session: Synthetic Scaffolds as Extracellular Matrices
• Presentation Title: "Human macrophages release higher IL-1ra over IL-1β when stimulated by block acetylated chitosan microparticles and not by random acetylated chitosans or water-soluble oligomers"
  Session: Role of Biomaterials in Inflammation

Poster Presentations

• Poster Title: "Anionic surfaces with minimal charge density can restore burst coagulation of microparticle/exosome-depleted blood plasma"
  Session: Building Blocks
• Poster Title: "Relationship of UDP-glucose dehydrogenase activity and in vitro hyaluronic acid release by human fibroblast-like synoviocytes"
  Session: Biomaterials and Host Response

About Ortho Regenerative Technologies Inc.
Ortho RTi is an orthopaedic biotechnology company dedicated to the development of medical devices that treat unmet needs in the orthopaedic market. Based on a proprietary biopolymer platform, the company is developing new regenerative treatments for soft tissue tears in the shoulder and knee as well as articular cartilage injuries, all currently with few clinically effective options for repair.

Caution regarding forward-looking statements
This news release may contain certain forward-looking statements regarding the Company's expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Company disclaims any intention or obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.

SOURCE Ortho RTI

Ed Margerrison, Ph.D., President and CEO, Ortho RTi, [email protected], 512-550-8005